Drug Trial Radar · NCT04082520
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
42
Planned (sponsor's estimate)
Start
Apr 14, 2020
Primary completion
Sep 4, 2027
Study completion Mar 4, 2032
Sponsor
- Lead sponsor
- Mayo ClinicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 9, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial studies how well lutathera works in treating patients with meningioma that cannot be treated with surgery (inoperable) and is growing, spreading, or getting worse (progressive) after external beam radiation therapy. Lutathera is a radioactive drug administered in the vein that is designed to target and kill tumor cells. The goal of this study is to determine whether this drug is safe and effective in treating meningiomas that progress after radiation treatment. WHO Grade I and Cohort WHO II/III cohorts will be evaluated.
Conditions
- Grade 1 Meningioma
- Grade 2 Meningioma
- Grade 3 Meningioma
- Recurrent Meningioma
- Unresectable Meningioma
Interventions
Gallium Ga 68-DOTATATERadiation
Given IV
Lutetium Lu 177 DotatateDrug
Given IV
Magnetic Resonance ImagingProcedure
Undergo PET/MRI
Positron Emission TomographyProcedure
Undergo PET/MRI
Questionnaire AdministrationOther
Ancillary studies
Computed TomographyProcedure
Undergo PET/CT and/or SPECT/CT
Biospecimen CollectionProcedure
Undergo blood sample collection
Single Photon Emission Computed TomographyProcedure
Undergo SPECT/CT
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival - 6 monthsTime frame: At 6 months after starting treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mayo Clinic in Rochester
Rochester, Minnesota · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.